Cargando…

S164: DISEASE MODIFYING ACTIVITY OF IMETELSTAT IN PATIENTS WITH HEAVILY TRANSFUSED NON-DEL(5Q) LOWER-RISK MYELODYSPLASTIC SYNDROMES RELAPSED/REFRACTORY TO ERYTHROPOIESIS STIMULATING AGENTS IN IMERGE PHASE 3

Detalles Bibliográficos
Autores principales:	Santini, Valeria, Platzbecker, Uwe, Fenaux, Pierre, Sekeres, Mikkael, Savona, Michael Robert, Madanat, Yazan, Campelo, María Díez, Valcárcel, David, Illmer, Thomas, Jonášová, Anna, Belohlavkova, Petra, Sherman, Laurie, Berry, Tymara, Dougherty, Souria, Shah, Sheetal, Xia, Qi, Peng, Lixian, Sun, Libo, Wan, Ying, Huang, Fei, Ikin, Annat, Navada, Shyamala, Feller, Faye, Zeidan, Amer M., Komrokji, Rami S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Oral Sessions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428251/ http://dx.doi.org/10.1097/01.HS9.0000967568.52578.93

Ejemplares similares

S165: CONTINUOUS TRANFUSION INDEPENDENCE WITH IMETELSTAT IN HEAVILY TRANSFUSED NON-DEL(5Q) LOWER-RISK MYELODYSPLASTIC SYNDROMES RELAPSED/REFRACTORY TO ERYTHROPOIESIS STIMULATING AGENTS IN IMERGE PHASE 3
por: Platzbecker, Uwe, et al.
Publicado: (2023)

P732: ANALYSIS OF PATIENT-REPORTED FATIGUE IN IMERGE PH3 TRIAL OF IMETELSTAT VS PLACEBO IN HEAVILY TRANSFUSED NON-DEL(5Q) LOWER-RISK MYELODYSPLASTIC SYNDROMES R/R TO ERYTHROPOIESIS STIMULATING AGENTS
por: Sekeres, Mikkael, et al.
Publicado: (2023)

PB2221: AN OPEN-LABEL, PHASE 1/1B STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND CLINICAL ACTIVITY OF IMETELSTAT IN COMBINATION WITH RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS: IMPROVEMF
por: Kuykendall, Andrew, et al.
Publicado: (2023)

PB2225: A RANDOMIZED OPEN-LABEL, PHASE 3 STUDY OF IMETELSTAT VS BEST AVAILABLE THERAPY IN INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS RELAPSED/REFRACTORY TO JAK INHIBITOR (IMPACTMF)
por: Mascarenhas, John, et al.
Publicado: (2023)

Evaluation of IMERG and ERA5 precipitation products over the Mongolian Plateau
por: Xin, Ying, et al.
Publicado: (2022)

Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis
por: Komrokji, Rami S., et al.
Publicado: (2022)

Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts
por: Zeidan, Amer M., et al.
Publicado: (2022)

Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial
por: Garcia-Manero, Guillermo, et al.
Publicado: (2022)

Dynamics of mutations in patients with essential thrombocythemia treated with imetelstat
por: Leibundgut, Elisabeth Oppliger, et al.
Publicado: (2020)

PB2014: A PHASE 2/3 TRIAL OF ORAL AZACITIDINE IN PATIENTS WITH LOW- OR INTERMEDIATE-RISK MYELODYSPLASTIC SYNDROMES
por: Garcia-Manero, Guillermo, et al.
Publicado: (2023)

Imetelstat therapy in refractory anemia with ring sideroblasts with or without thrombocytosis
por: Tefferi, A, et al.
Publicado: (2016)

Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care
por: Nazha, Aziz, et al.
Publicado: (2017)

Imetelstat (a telomerase antagonist) exerts off-target effects on the cytoskeleton
por: MENDER, ILGEN, et al.
Publicado: (2013)

The evaluation of IMERG and ERA5-Land daily precipitation over China with considering the influence of gauge data bias
por: Xie, Wenhao, et al.
Publicado: (2022)

Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapy
por: Prebet, Thomas, et al.
Publicado: (2017)

Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy
por: Prebet, Thomas, et al.
Publicado: (2017)

Telomerase antagonist imetelstat increases radiation sensitivity in esophageal squamous cell carcinoma
por: Wu, Xuping, et al.
Publicado: (2017)

Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the MEDALIST Phase 3 Trial
por: Oliva, Esther Natalie, et al.
Publicado: (2021)

Telomerase Inhibitor Imetelstat (GRN163L) Limits the Lifespan of Human Pancreatic Cancer Cells
por: Burchett, Katrina M., et al.
Publicado: (2014)

Myelosuppression in Patients Treated with the Telomerase Inhibitor Imetelstat Is Not Mediated through Activation of Toll-Like Receptors
por: Baerlocher, Gabriela M., et al.
Publicado: (2020)

S169: MODULATION OF THE IMMUNE LANDSCAPE IN LOWER-RISK MYELODYSPLASTIC SYNDROMES WITH IMETELSTAT-INDUCED TRANSFUSION INDEPENDENCY
por: Chapuis, Nicolas, et al.
Publicado: (2023)

Under COVID of the night
por: Sekeres, Mikkael A.
Publicado: (2020)

Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1–risk myelodysplastic syndrome and thrombocytopenia
por: Giagounidis, Aristoteles, et al.
Publicado: (2014)

The Alzheimer Amyloid Precursor Protein (APP) and Fe65, an APP-Binding Protein, Regulate Cell Movement
por: Sabo, Shasta L., et al.
Publicado: (2001)

Imetelstat Induces Leukemia Stem Cell Death in Pediatric Acute Myeloid Leukemia Patient-Derived Xenografts
por: Barwe, Sonali P., et al.
Publicado: (2022)

S102: LUSPATERCEPT VERSUS EPOETIN ALFA FOR TREATMENT (TX) OF ANEMIA IN ESA-NAIVE LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS (PTS) REQUIRING RBC TRANSFUSIONS: DATA FROM THE PHASE 3 COMMANDS STUDY
por: Della Porta, Matteo Giovanni, et al.
Publicado: (2023)

Relationship of different platelet response criteria and patient outcomes in a romiplostim myelodysplastic syndromes trial
por: Platzbecker, U, et al.
Publicado: (2014)

Telomerase-targeting compounds Imetelstat and 6-thio-dG act synergistically with chemotherapy in high-risk neuroblastoma models
por: Fischer-Mertens, Janina, et al.
Publicado: (2022)

Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long‐term safety and efficacy
por: Fenaux, Pierre, et al.
Publicado: (2017)

Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin
por: Duong, Hien K, et al.
Publicado: (2009)

P1048: MYF3001: A RANDOMIZED OPEN LABEL, PHASE 3 STUDY TO EVALUATE IMETELSTAT VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS REFRACTORY TO JANUS KINASE INHIBITOR
por: Mascarenhas, J., et al.
Publicado: (2022)

Extrapolations to the Z = 164 region
por: Bengtsson, R
Publicado: (1970)

164th RB Meeting
por: CERN. Geneva. Research Board
Publicado: (2003)

IAU Symposium 164 : Stellar Populations
Publicado: (1994)

Health Tract, No. 164: Sickness Not Causeless
Publicado: (1863)

Health Tract, No. 164: Sickness Not Causeless
Publicado: (1865)

Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts
por: Platzbecker, Uwe, et al.
Publicado: (2023)

Improved benefit of continuing luspatercept therapy: sub-analysis of patients with lower-risk MDS in the MEDALIST study
por: Germing, Ulrich, et al.
Publicado: (2023)

Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts
por: Zeidan, Amer M, et al.
Publicado: (2020)

164th Symposium of the International Astronomical Union
por: Kruit, P, et al.
Publicado: (1995)

Cannot write session to /tmp/vufind_sessions/sess_r63co21b9snmf364k58i3ohfme